Clinical Scorecard: Meet the Team: Shernan Holtan, MD

At a Glance

Key Highlights

• Significant reduction in GVHD incidence from 50% to 5-10% with new prophylaxis regimens.
• Focus on improving patient care and quality of life during treatment.
• Innovative research on using medications with dual effects on GVHD and leukemia.
• Emphasis on supportive care, nutrition, and exercise for transplant patients.
• Goal to reduce recovery time by 50% and streamline medication regimens.

Guideline-Based Recommendations

Diagnosis

• Monitor patients closely for GVHD post-transplant.

Management

• Utilize post transplant cyclophosphamide for GVHD prophylaxis.
• Incorporate medications that enhance immune function.

Monitoring & Follow-up

• Patients require close monitoring for 100 days post-transplant.

Risks

• Patients may experience complications requiring extended care.

Patient & Prescribing Data

Patients undergoing allogeneic transplantation.

Aim to minimize the number of medications and side effects while enhancing recovery.

Clinical Best Practices

• Focus on nutritional support and exercise during recovery.
• Streamline medication regimens to reduce side effects.
• Incorporate cell therapies to reduce relapse and infection risk.

References

• Roswell Park Comprehensive Cancer Center